China Regenerative Medicine International (HKSE:08158) Total Inventories : HK$0.30 Mil (As of Jun. 2024)

View and export this data going back to 2001. Start your Free Trial

What is China Regenerative Medicine International Total Inventories?

China Regenerative Medicine International's total inventories for the quarter that ended in Jun. 2024 was HK$0.30 Mil. China Regenerative Medicine International's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Jun. 2024 was HK$0.37 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. China Regenerative Medicine International's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was HK$-0.38.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. China Regenerative Medicine International's Inventory Turnover for the quarter that ended in Jun. 2024 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

China Regenerative Medicine International Total Inventories Historical Data

The historical data trend for China Regenerative Medicine International's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Regenerative Medicine International Total Inventories Chart

China Regenerative Medicine International Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

6.74

1.38

0.38

0.29

0.45

China Regenerative Medicine International Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Total Inventories	Get a 7-Day Free Trial															-	0.45	-	0.45	0.30

China Regenerative Medicine International Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

China Regenerative Medicine International (HKSE:08158) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

China Regenerative Medicine International's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is

	Net-Net Working Capital Per Share (Q: Jun. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1.847	+	0.75 * 1.551	+	0.5 * 0.296	-	119.939
-	0	-	0)	/	304.252
=	-0.38

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

China Regenerative Medicine International's Days Inventory for the three months ended in Jun. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2024 )	/	Cost of Goods Sold (Q: Jun. 2024 )	*	Days in Period
	=	0.3705	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

China Regenerative Medicine International's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2024 )	/	Average Total Inventories (Q: Jun. 2024 )
	=	0	/	0.3705
	=	0.00

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

China Regenerative Medicine International's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	0.3705	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

China Regenerative Medicine International Total Inventories Related Terms

Thank you for viewing the detailed overview of China Regenerative Medicine International's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

China Regenerative Medicine International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Regenerative Medicine International Ltd (HKSE:08158) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

132 Nathan Road, Suite 2310–18, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG

Website

https://www.crmi.hk

China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.

Executives

Wang Chuang	2101 Beneficial owner
Wong Kwok Keung	2501 Other
Arab Osman Mohammed	2501 Other
Chang Zhou Shi Zhong Min Xing Kong Qi Ye Guan Li Zi Xun Fu Wu He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Lei Changjuan	2101 Beneficial owner
Chang Zhou Shi Yao Guang Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Kong Yudong	2101 Beneficial owner
Li Ren	2201 Interest of corporation controlled by you
Nat-ace Wood Industry Ltd. (formerly Known As Forerunner Technology Limited)	2201 Interest of corporation controlled by you
All Favour Holdings Limited	2101 Beneficial owner
Deng Shufen	2202 Interest of your spouse
Dai Yumin	2201 Interest of corporation controlled by you
Wang Xiaogang	2101 Beneficial owner
China Orient Asset Management Co., Ltd.	2106 Person having a security interest in shares
China Orient Alternative Investment Fund	2106 Person having a security interest in shares

China Regenerative Medicine International Headlines

No Headlines